Juliette Audet Forbion Presents at the BIOTECH MEDTECH HEALTHTECH LeZoom19H Conferences

## Title: Exploring the Investment Strategy of Forbion, a Leading European Biotech Venture Capital Firm with Juliette Audet

### Description:

Welcome to this conference where we delve into the investment strategy of Forbion, a prominent European venture capital firm with a strong focus on biotechnology. With €1.7 billion under management, Forbion has been making headlines in recent months with its growth fund of €305 million and the successful closing of Forbion V at €450 million.

Throughout its history, Forbion has been involved in all stages of biotech companies, from inception to crossover and beyond, with a specific emphasis on drug development. Some of Forbion’s early investments include Argenx (ARGX; market cap €10 million), Uniqure (QURE; market cap €2 billion), as well as clinical-stage companies like Promedior (acquired by Roche for €1.4 billion), Dezima Pharma (acquired by Amgen for €1.55 billion), and Prexton Therapeutics (acquired by Lundbeck for €905 million).

Join us as we analyze the investment strategy of this influential player in the European biotech landscape, with Juliette Audet, Partner at Forbion.

[](youtube_link)

### Topics:
Biotech Finances, Biotech, Healthtech, Medtech, Finances, Investir, Investisseurs, Biotechnologies, Investir Biotech, Investir Medtech, Actualité Biotech, Levée de Fonds, Conférences Biotech, Conférence Medtech, LeZoom19H, Le Zoom 19H, Dans quelle biotech investir, info biotech, entreprise biotechnologie, startup biotechnologie, industrie biotechnologie, entreprise biotech, news biotech, journal biotech, Juliette Audet, Forbion, Uniqure, Dezima, Promedior.

### Transcript:
[Full transcript available here](transcript_link)

### Want to learn more about biotech and medtech?
Check out our [online conferences](conference_link) for in-depth discussions on the latest trends in the industry.

[Source: Biotech Finances](source_link)

Forbion, qui dispose de 1,7 Md€ sous gestion a fait l’actualité ces derniers mois avec son fonds growth à 305 M€ et Forbion V bouclé à 450 M€. Ce VC qui balaye l’ensemble de la vie des biotechs depuis la création, jusqu’au crossover et au-delà, se focalise sur le médicament. Parmi les investissements de la première heure de Forbion se trouvent Argenx (ARGX; capitalisation boursière 10 M), Uniqure (QURE; capitalisation boursière 2 Mds$) ainsi que des entreprises au stade clinique telles que Promedior (acquise par Roche pour 1,4 md€ ), Dezima Pharma (acquis par Amgen pour 1,55 Md€ et Prexton Therapeutics (acquis par Lundbeck pour 905 M€).

Nous décryptons et analysons la stratégie d’investissement de cet acteur clef du paysage européen avec Juliette Audet, Partner chez Forbion.
#BiotechFinances​

Fans de #BIOTECH​​, #HEALTHTECH​​ et #MEDTECH​​, retrouvez toutes nos conférences en ligne en 🆅🅴🆁🆂🅸🅾🅽 🅸🅽🆃é🅶🆁🅰🅻🅴 :
https://bit.ly/3mHIsZ0